Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t gotten the message yet.

The Cambridge, Massachusetts-based company announced this morning that it is halting its work on Ionis Pharmaceuticals-partnered oligonucleotides for two different diseases. That includes the amyotrophic lateral sclerosis (ALS) drug BIIB105, which was designed to reduce expression of the ATXN2 gene.